Core Insights - Armata Pharmaceuticals reported financial results for Q2 2024, highlighting advancements in its clinical programs and financial performance [1][2][3]. Clinical Developments - Enrollment in the Tailwind Phase 2 clinical study of inhaled AP-PA02 for patients with Non-Cystic Fibrosis Bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection has been completed, with topline data expected in H2 2024 [2][3]. - The company received $5.25 million in non-dilutive funding from the U.S. Department of Defense to support the Phase 2a diSArm study of intravenous AP-SA02 for Staphylococcus aureus bacteremia [2][3]. - Armata has made progress in bacteriophage science through presentations at industry conferences and has completed the build-out of its cGMP manufacturing facility [2][3]. Financial Performance - Grant revenue for Q2 2024 was $0, compared to approximately $1.0 million in Q2 2023 [4]. - Research and development expenses increased to approximately $8.5 million in Q2 2024 from approximately $8.3 million in Q2 2023 [4]. - General and administrative expenses rose to approximately $3.4 million in Q2 2024, up from approximately $2.4 million in Q2 2023, primarily due to increased stock-based compensation [5]. - Loss from operations for Q2 2024 was $11.9 million, compared to a loss of approximately $9.6 million in Q2 2023 [6]. - As of June 30, 2024, the company held approximately $26.4 million in unrestricted cash and cash equivalents, a significant increase from $13.5 million at the end of 2023 [6]. Company Overview - Armata Pharmaceuticals is focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections, with a pipeline that includes candidates for Pseudomonas aeruginosa and Staphylococcus aureus [7].

Core Viewpoint - Armata Pharmaceuticals has received $5.25 million in non-dilutive funding from the Department of Defense to support the clinical development of its phage therapy candidate, AP-SA02, for treating complicated Staphylococcus aureus bacteremia [1][2]. Group 1: Funding and Support - The funding is part of a grant managed by the Naval Medical Research Command and aims to advance the clinical development of AP-SA02 [1]. - The grant is intended to help address the urgent need for effective treatments for Staphylococcus aureus bacteremia, which is often resistant to existing antibiotics [2]. Group 2: Clinical Trial Details - The diSArm study is a Phase 1b/2a clinical trial designed to evaluate the safety, tolerability, and efficacy of AP-SA02 as an adjunct to best available antibiotic therapy [2][3]. - Phase 1b focuses on safety and tolerability, while Phase 2a will assess efficacy in subjects with complicated Staphylococcus aureus bacteremia [3]. - The study aims to enroll approximately 50 subjects and is currently 68% enrolled [3]. Group 3: Company Overview - Armata Pharmaceuticals specializes in developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections [4]. - The company is advancing a pipeline of phage candidates targeting various pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa [4].

Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections [1][2] - The company will present at the Viruses of Microbes 2024 conference, highlighting advancements in bacteriophage therapy from discovery to clinical trials [1] Company Overview - Armata is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [2] - The company utilizes proprietary bacteriophage-based technology and has in-house cGMP manufacturing capabilities for drug development [2]

Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES, March 4, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportun ...

Company Overview - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections using proprietary technology [3]. Upcoming Presentation - Dr. Mina Pastagia, Chief Medical Officer of Armata, will present at the 6th Annual Bacteriophage Therapy Summit on February 28, 2024, covering the clinical trials and advantages of Armata's bacteriophage candidates [1]. - The presentation will include topics such as the multi-phage cocktail approach for chronic Pseudomonal respiratory infections and the safety of intravenous dosing of Armata's S. aureus phage candidate [1]. Industry Context - The 2024 Bacteriophage Therapy Summit aims to optimize safety, efficacy, and manufacturing of next-generation bacteriophage therapies, with a focus on demonstrating positive clinical data and patient outcomes [2]. - The summit will feature over 90 phage experts and is positioned as a global platform for phage drug developers, emphasizing advancements in clinical and regulatory development, manufacturability, and innovative applications [2].

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 4:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial Officer, AmpliPhi Biosciences Todd Patrick - President and Chief Executive Officer, C3J Therapeutics Brian Varnum - Chief Development Officer, C3J Therapeutics Conference Call Participants Joe Pantginis - HC Wainwright Michael Higgins ...